BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 27514395)

  • 1. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
    Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
    Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
    BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
    Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
    Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
    Liu D
    Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
    El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
    Aleskandarany MA; Agarwal D; Negm OH; Ball G; Elmouna A; Ashankyty I; Nuglozeh E; Fazaludeen MF; Diez-Rodriguez M; Nolan CC; Tighe PJ; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Feb; 156(1):9-20. PubMed ID: 26907764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.
    Kurozumi S; Joseph C; Raafat S; Sonbul S; Kariri Y; Alsaeed S; Pigera M; Alsaleem M; Nolan CC; Johnston SJ; Aleskandarany MA; Ogden A; Fujii T; Shirabe K; Martin SG; Alshankyty I; Mongan NP; Ellis IO; Green AR; Rakha EA
    Breast Cancer Res Treat; 2019 Jul; 176(1):63-73. PubMed ID: 30941650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
    Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
    J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the AR/ER ratio in ER-positive breast cancer patients.
    Rangel N; Rondon-Lagos M; Annaratone L; Osella-Abate S; Metovic J; Mano MP; Bertero L; Cassoni P; Sapino A; Castellano I
    Endocr Relat Cancer; 2018 Mar; 25(3):163-172. PubMed ID: 29386247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
    Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
    Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
    [No Abstract]   [Full Text] [Related]  

  • 14. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of androgen receptor and its phosphorylated forms in breast cancer progression.
    Ren Q; Zhang L; Ruoff R; Ha S; Wang J; Jain S; Reuter V; Gerald W; Giri DD; Melamed J; Garabedian MJ; Lee P; Logan SK
    Cancer; 2013 Jul; 119(14):2532-40. PubMed ID: 23605249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors.
    Rangel N; Rondon-Lagos M; Annaratone L; Aristizábal-Pachon AF; Cassoni P; Sapino A; Castellano I
    Cells; 2020 Apr; 9(4):. PubMed ID: 32344660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.
    Aleskandarany MA; Sonbul S; Surridge R; Mukherjee A; Caldas C; Diez-Rodriguez M; Ashankyty I; Albrahim KI; Elmouna AM; Aneja R; Martin SG; Ellis IO; Green AR; Rakha EA
    Br J Cancer; 2017 Oct; 117(8):1176-1184. PubMed ID: 28829761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
    Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
    Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers.
    Witzel I; Graeser M; Karn T; Schmidt M; Wirtz R; Schütze D; Rausch A; Jänicke F; Milde-Langosch K; Müller V
    J Cancer Res Clin Oncol; 2013 May; 139(5):809-16. PubMed ID: 23392859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer.
    Abduljabbar R; Al-Kaabi MM; Negm OH; Jerjees D; Muftah AA; Mukherjee A; Lai CF; Buluwela L; Ali S; Tighe PJ; Green A; Ellis I; Rakha E
    Breast Cancer Res Treat; 2015 Apr; 150(3):511-22. PubMed ID: 25794775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.